Synlait Milk has obtained waivers from its syndicated banks on key financial covenants for the quarter ending April 2026, reflecting ongoing operational and market challenges.
- Waivers granted on quarterly EBITDA and interest cover ratio
- Financial performance impacted by external headwinds
- Waivers apply to April 2026 test date
- Reflects continued pressure on Synlait’s earnings
- No detailed metrics or waiver duration disclosed
Banking Covenants Waived for April Quarter
Synlait Milk Limited (NZX:SML, ASX:SM1) has secured two crucial waivers from its syndicated banking group, allowing it to bypass the quarterly minimum EBITDA covenant and the interest cover ratio test for the period ending 30 April 2026. These waivers come as the company continues to grapple with financial headwinds beyond its control, which have weighed on its earnings and cash flow.
The interest cover ratio waiver means Synlait’s ability to cover interest expenses with earnings before interest, tax, depreciation, and amortisation (EBITDA) fell short of the bank’s usual requirements. The EBITDA event of review waiver similarly signals that the company did not meet the expected profitability threshold for the quarter. While the announcement does not specify the exact figures or the length of the waivers, the need for these concessions underscores ongoing pressure on Synlait’s financial performance.
Persistent External Challenges Impact Earnings
Synlait has previously highlighted supply chain disruptions and testing delays in its infant formula segment, which have contributed to volatile market conditions and uncertain revenue streams. The company’s latest waivers align with its interim results, which flagged these operational challenges and the absence of full-year guidance. The extended testing delays and supply chain issues have hampered product releases and customer inventory rebuilds, compounding the earnings pressure.
This situation is consistent with the broader industry environment, where regulatory shifts and geopolitical tensions continue to unsettle the infant formula market. Synlait’s ability to negotiate these waivers reflects a degree of confidence from its lenders but also signals that the company remains vulnerable to these external shocks. The waivers provide breathing room but do not resolve the underlying market volatility that Synlait faces.
Next Steps and Investor Considerations
Investors should monitor Synlait’s forthcoming financial disclosures for updates on covenant compliance and any further changes to its banking arrangements. The company’s management has not indicated whether these waivers will extend beyond the April 2026 test date, leaving some uncertainty about future liquidity and credit metrics.
Synlait’s response to ongoing headwinds, including any operational improvements or strategic adjustments, will be critical in regaining financial stability. The company’s ability to navigate supply chain complexities and market volatility will likely shape its covenant status in subsequent quarters. This development follows recent reports of infant formula market volatility that continue to challenge Synlait’s performance.
Bottom Line?
Synlait’s banking waivers offer temporary relief but spotlight sustained earnings pressure amid an unsettled market.
Questions in the middle?
- Will Synlait require further covenant relief beyond April 2026?
- How effectively can Synlait mitigate supply chain and testing delays?
- What impact will ongoing market volatility have on Synlait’s credit profile?